Trial reportGynecologic oncology2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Trial report in Gynecologic oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00979992 (A Phase II Evaluation of SU11248), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma
Who cites it
40 citing papers in PubMed.
- Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017/GCIG.Journal of gynecologic oncology · 2020Trial
- Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).Gynecologic oncology · 2018Trial
- Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026Review
- Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.The oncologist · 2025Review
- Clinicopathological factors of ovarian clear cell carcinoma: A single institutional analysis of 247 cases in China.Biomolecules & biomedicine · 2025Article
- Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies.Case reports in obstetrics and gynecology · 2025Article
- Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.Journal of gynecologic oncology · 2024Article
- Proteomic landscape of epithelial ovarian cancer.Nature communications · 2024Article
- Status and development of research on clear cell carcinoma of the ovary-a visualization-based bibliometric analysis.Translational cancer research · 2024Article
- From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.Journal of ovarian research · 2024Review
- Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.Annals of medicine · 2023Article
- Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.Gynecologic oncology reports · 2023Article
- Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.BMC women's health · 2023Article
- Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series.Gynecologic oncology reports · 2023Article
- Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine.Frontiers in pharmacology · 2023Review
- Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises.Cancers · 2022Review
- Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?Biomedicines · 2022Review
- Article
- Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesTo determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients.
methodsAll patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and clinical response. The study was designed to determine if the drug had a response rate of at least 20% or 6-month PFS of at least 25%.
resultsOf 35 patients enrolled, 30 were treated and eligible (median age: 51, range: 27-73). Twenty-five (83%) were White, 4 (13%) Asian, and 1 (3%) unknown. The majority 28 (83%) patients, underwent ≤3 but 2 (7%) had 16 courses of study therapy. Five (16.7%) patients had PFS ≥6 months (90% CI: 6.8%-31.9%). Two (6.7%) patients had a partial or complete response (90% CI: 1.2%-19.5%). The median PFS was 2.7 months. The median overall survival was 12.8 months. The most common grade 3 adverse events were fatigue (4), hypertension (4), neutropenia (4), anemia (3), abdominal pain (3), and leukopenia (3). Grade 4-5 adverse events included: thrombocytopenia (5), anemia (2), acute kidney Injury (1), stroke (1), and allergic reaction (1).
conclusionSunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.